
Coherus BioSciences (CHRS) Stock Forecast & Price Target
Coherus BioSciences (CHRS) Analyst Ratings
Bulls say
Coherus Oncology is attractive fundamentally because it combines an approved, commercial PD-1 franchise with a pipeline that could materially expand value through multiple shots on goal, led by tagmokitug in esophageal cancer and casdozokitug in liver cancer. Loqtorzi is already growing, with 3Q net revenue of $14.0M (+3% QoQ, +25% YoY), and management expects quarterly sales to rise further while the company lowers core cash burn by $6M-$7M per quarter after a ~30% headcount reduction. The thesis is strengthened by differentiated clinical data, including 1L ESCC response rates up to 89% and 1L HCC activity with a 37.9% ORR and 17.2% CR rate, which suggests the pipeline could drive meaningful long-term revenue beyond the current $179M market cap.
Bears say
Coherus Oncology is burdened by a high clinical and regulatory risk profile, because the investment case still hinges on small, interim, largely single-arm data that may not hold up in larger or randomized studies, while even a strong pooled ORR would be insufficient if the control arm performs similarly. Financially, the company remains loss-making, with a $33.3M net loss from continuing operations in 2Q26 and $183.1M in 2025, and it ended 2Q26 with $105.3M in cash and $37.2M of debt, implying only limited near-term flexibility despite management’s guidance. The outlook is further weakened by intense competition, dependence on future approvals and manufacturing/regulatory milestones, and an expected need for additional equity capital that could dilute shareholders if pipeline development continues to require funding.
This aggregate rating is based on analysts' research of Coherus BioSciences and is not a guaranteed prediction by Public.com or investment advice.
Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction
Start investing in Coherus BioSciences (CHRS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Coherus BioSciences (CHRS) Forecast
Coherus BioSciences (CHRS) Analyst Forecast & Price Prediction
Start investing in Coherus BioSciences (CHRS)
Order type
Buy in
Order amount
Est. shares
0 shares